Lantern Pharma has reported third-quarter 2025 results showcasing substantial progress across its AI-driven oncology pipeline, highlighted by the successful completion of enrollment in the LP-184 Phase 1a trial. The trial demonstrated a 48% clinical benefit rate at or above the therapeutic dose threshold, along with a favorable safety profile and strong biomarker correlations. These results validate the company’s approach to leveraging artificial intelligence in drug development.
The company has outlined plans for Phase 1b/2 studies targeting triple-negative breast cancer, non-small cell lung cancer with STK11/KEAP1 co-mutations, and bladder cancer. Pharmacokinetic data has established a recommended Phase 2 dose of 0.39 mg/kg for these upcoming trials. Lantern Pharma described its pipeline as catalyst-rich, with multiple programs advancing simultaneously through clinical development stages.
Regulatory progress includes clarity for the company’s pediatric central nervous system cancer program following a productive FDA Type C meeting. Additionally, commercial interest has increased for LP-284, another promising candidate in the pipeline. The company’s proprietary AI and machine learning platform, RADR, leverages over 200 billion oncology-focused data points and a library of more than 200 advanced ML algorithms to accelerate drug development.
Lantern Pharma’s approach represents a significant shift in oncology drug development, potentially reducing both costs and timelines while improving success rates. The company maintains its newsroom at https://ibn.fm/LTRN where investors can access the latest updates. The broader investment community can find additional resources through platforms like https://www.InvestorWire.com, which provides specialized communications services for public companies.
The successful clinical outcomes combined with the AI-driven methodology position Lantern Pharma to potentially address multiple high-need cancer indications. The company’s pipeline spans both solid tumors and blood cancers, including an antibody-drug conjugate program, with combined annual market potential estimated at over $15 billion. This approach could ultimately provide life-changing therapies to hundreds of thousands of cancer patients worldwide while demonstrating the practical application of AI in pharmaceutical development.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Lantern Pharma Reports Strong Q3 2025 Results with AI-Driven Oncology Programs Showing Clinical Promise.